279 related articles for article (PubMed ID: 34643690)
1. Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow.
Langerhorst P; Noori S; Zajec M; De Rijke YB; Gloerich J; van Gool AJ; Caillon H; Joosten I; Luider TM; Corre J; VanDuijn MM; Dejoie T; Jacobs JFM
Clin Chem; 2021 Nov; 67(12):1689-1698. PubMed ID: 34643690
[TBL] [Abstract][Full Text] [Related]
2. M-protein diagnostics in multiple myeloma patients using ultra-sensitive targeted mass spectrometry and an off-the-shelf calibrator.
Wijnands C; Langerhorst P; Noori S; Keizer-Garritsen J; Wessels HJCT; Gloerich J; Bonifay V; Caillon H; Luider TM; van Gool AJ; Dejoie T; VanDuijn MM; Jacobs JFM
Clin Chem Lab Med; 2024 Feb; 62(3):540-550. PubMed ID: 37823394
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation.
Takamatsu H; Takezako N; Zheng J; Moorhead M; Carlton VEH; Kong KA; Murata R; Ito S; Miyamoto T; Yokoyama K; Matsue K; Sato T; Kurokawa T; Yagi H; Terasaki Y; Ohata K; Matsumoto M; Yoshida T; Faham M; Nakao S
Ann Oncol; 2017 Oct; 28(10):2503-2510. PubMed ID: 28945825
[TBL] [Abstract][Full Text] [Related]
4. Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM).
Fan H; Wang B; Shi L; Pan N; Yan W; Xu J; Gong L; Li L; Liu Y; Du C; Cui J; Zhu G; Deng S; Sui W; Xu Y; Yi S; Hao M; Zou D; Chen X; Qiu L; An G
Clin Cancer Res; 2024 Mar; 30(6):1131-1142. PubMed ID: 38170583
[TBL] [Abstract][Full Text] [Related]
5. MRD Assessment in Multiple Myeloma: Progress and Challenges.
Bertamini L; D'Agostino M; Gay F
Curr Hematol Malig Rep; 2021 Apr; 16(2):162-171. PubMed ID: 33950462
[TBL] [Abstract][Full Text] [Related]
6. Validation of a PCR-Based Next-Generation Sequencing Approach for the Detection and Quantification of Minimal Residual Disease in Acute Lymphoblastic Leukemia and Multiple Myeloma Using gBlocks as Calibrators.
Van der Straeten J; De Brouwer W; Kabongo E; Dresse MF; Fostier K; Schots R; Van Riet I; Bakkus M
J Mol Diagn; 2021 May; 23(5):599-611. PubMed ID: 33549860
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.
Perrot A; Lauwers-Cances V; Corre J; Robillard N; Hulin C; Chretien ML; Dejoie T; Maheo S; Stoppa AM; Pegourie B; Karlin L; Garderet L; Arnulf B; Doyen C; Meuleman N; Royer B; Eveillard JR; Benboubker L; Dib M; Decaux O; Jaccard A; Belhadj K; Brechignac S; Kolb B; Fohrer C; Mohty M; Macro M; Richardson PG; Carlton V; Moorhead M; Willis T; Faham M; Anderson KC; Harousseau JL; Leleu X; Facon T; Moreau P; Attal M; Avet-Loiseau H; Munshi N
Blood; 2018 Dec; 132(23):2456-2464. PubMed ID: 30249784
[TBL] [Abstract][Full Text] [Related]
8. Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma.
Yao Q; Bai Y; Orfao A; Kumar S; Chim CS
J Mol Diagn; 2020 May; 22(5):679-684. PubMed ID: 32151713
[TBL] [Abstract][Full Text] [Related]
9. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma.
Medina A; Puig N; Flores-Montero J; Jimenez C; Sarasquete ME; Garcia-Alvarez M; Prieto-Conde I; Chillon C; Alcoceba M; Gutierrez NC; Oriol A; Rosinol L; Bladè J; Gironella M; Hernandez MT; Gonzalez-Calle V; Cedena MT; Paiva B; San-Miguel JF; Lahuerta JJ; Mateos MV; Martinez-Lopez J; Orfao A; Gonzalez M; Garcia-Sanz R
Blood Cancer J; 2020 Oct; 10(10):108. PubMed ID: 33127891
[TBL] [Abstract][Full Text] [Related]
10. Clonotypic Light Chain Peptides Identified for Monitoring Minimal Residual Disease in Multiple Myeloma without Bone Marrow Aspiration.
Bergen HR; Dasari S; Dispenzieri A; Mills JR; Ramirez-Alvarado M; Tschumper RC; Jelinek DF; Barnidge DR; Murray DL
Clin Chem; 2016 Jan; 62(1):243-51. PubMed ID: 26430073
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma.
Martinez-Lopez J; Lahuerta JJ; Pepin F; González M; Barrio S; Ayala R; Puig N; Montalban MA; Paiva B; Weng L; Jiménez C; Sopena M; Moorhead M; Cedena T; Rapado I; Mateos MV; Rosiñol L; Oriol A; Blanchard MJ; Martínez R; Bladé J; San Miguel J; Faham M; García-Sanz R
Blood; 2014 May; 123(20):3073-9. PubMed ID: 24646471
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.
Waldschmidt JM; Anand P; Knoechel B; Lohr JG
Semin Hematol; 2018 Jan; 55(1):33-37. PubMed ID: 29759150
[TBL] [Abstract][Full Text] [Related]
13. M-protein detection by mass spectrometry for minimal residual disease in multiple myeloma.
Guan L; Su W; Zhong J; Qiu L
Clin Chim Acta; 2024 Jan; 552():117623. PubMed ID: 37924928
[TBL] [Abstract][Full Text] [Related]
14. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
Anderson KC; Auclair D; Kelloff GJ; Sigman CC; Avet-Loiseau H; Farrell AT; Gormley NJ; Kumar SK; Landgren O; Munshi NC; Cavo M; Davies FE; Di Bacco A; Dickey JS; Gutman SI; Higley HR; Hussein MA; Jessup JM; Kirsch IR; Little RF; Loberg RD; Lohr JG; Mukundan L; Omel JL; Pugh TJ; Reaman GH; Robbins MD; Sasser AK; Valente N; Zamagni E
Clin Cancer Res; 2017 Aug; 23(15):3980-3993. PubMed ID: 28428191
[TBL] [Abstract][Full Text] [Related]
15. Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma.
Hultcrantz M; Rustad EH; Yellapantula V; Jacob A; Akhlaghi T; Korde N; Mailankody S; Lesokhin AM; Hassoun H; Smith EL; Lahoud OB; Landau HJ; Shah GL; Scordo M; Chung DJ; Giralt S; Papaemmanuil E; Landgren O
Clin Cancer Res; 2022 May; 28(10):2160-2166. PubMed ID: 35553646
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
Schmitz A; Brøndum RF; Johnsen HE; Mellqvist UH; Waage A; Gimsing P; Op Bruinink DH; van der Velden V; van der Holt B; Hansson M; Andersen NF; Frølund UC; Helleberg C; Schjesvold FH; Ahlberg L; Gulbrandsen N; Andreasson B; Lauri B; Haukas E; Bødker JS; Roug AS; Bøgsted M; Severinsen MT; Gregersen H; Abildgaard N; Sonneveld P; Dybkær K
BMC Cancer; 2022 Feb; 22(1):147. PubMed ID: 35123422
[TBL] [Abstract][Full Text] [Related]
17. [Impact of minimal residual disease detection after treatment of multiple myeloma].
Szendrei T; Plander M; Szabó Z; Kereskai L; Kajtár B; Papp G; Iványi JL
Orv Hetil; 2019 Mar; 160(13):502-508. PubMed ID: 30907098
[TBL] [Abstract][Full Text] [Related]
18. Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients with Multiple Myeloma.
Kim HY; Yoo IY; Lim DJ; Kim HJ; Kim SH; Yoon SE; Kim SJ; Cho D; Kim K
Ann Lab Med; 2022 Sep; 42(5):558-565. PubMed ID: 35470273
[TBL] [Abstract][Full Text] [Related]
19. Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing.
Oliva S; Genuardi E; Paris L; D'Agostino M; Rogers J; Rota-Scalabrini D; Jacob AP; Patriarca F; Luppi M; Bertazzoni P; Velluti C; Capra A; Saraci E; Rossi M; Allegra A; Mina R; Gentile M; Kirsch IR; Belotti A; Cavo M; Bruno B; Musto P; Boccadoro M; Zamagni E; Gay F
EClinicalMedicine; 2023 Jun; 60():102016. PubMed ID: 37396800
[TBL] [Abstract][Full Text] [Related]
20. Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity.
Diamond BT; Rustad E; Maclachlan K; Thoren K; Ho C; Roshal M; Ulaner GA; Landgren CO
Blood Rev; 2021 Mar; 46():100732. PubMed ID: 32771227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
